Studies have shown that Prolia® (denosumab) effectively decreases fracture risk in postmenopausal women
Prolia® (denosumab) treatment for osteoporosis has been compared with placebo in over postmenopausal 8,000 women. The main measure of efficacy in these women was the number of new fractures, particularly spinal fractures and hip fractures. Results were similar to or better than what has earlier been demonstrated for other drugs approved for the osteoporosis treatment in postmenopausal women at increased risk of fracture. The fact that women had a lower average body weight than men in studies (mean 69.8 vs. 85.2 kg) did not alter the pharmacokinetics of Prolia® (denosumab).